Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 22Thoracic 7Gastrointestinal 5Tumor-Agnostic 4Lymphoid 4Genitourinary 4CNS 4Head & Neck 3Dermatologic 3Sarcoma 2Gynecologic 2Plasma cell 1Other solid neoplasm 1Endocrine 1

Conditions

Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma 2Mesothelioma, Malignant 1Mesothelioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Rituximab 702Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Granulocyte Colony-Stimulating Factor 145Lenalidomide 144Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 111Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × abemaciclib × Lymphoid × Clear all
NCT01739309 2023-09-21

Study of LY2835219 for Mantle Cell Lymphoma

Eli Lilly and Company

Phase 2 Completed
28 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

NCT02014129 2020-08-24

A Study of LY2835219 in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
12 enrolled 11 charts
Lymphoid

Lymphoma, Neoplasm Metastasis

NCT02745769 2019-03-05

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Eli Lilly and Company

Phase 1 Completed
23 enrolled
GastrointestinalLymphoid

Colorectal Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡